Skip to main content

Advertisement

SpringerLink
Log in

Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis

  • Research Article
  • Published:
Tumor Biology

Abstract

Pancreatic cancer is a highly malignant cancer with increasing incidence and mortality worldwide. Carbohydrate antigen 19-9 (CA19-9) has been widely reported to play a role in the diagnosis of pancreatic cancer patients. However, published data on this subject are inconclusive. There was no meta-analysis that has been previously performed to evaluate critically the diagnostic accuracy of CA19-9 for pancreatic cancer. Therefore, we performed a meta-analysis to evaluate the sensitivity and specificity of CA19-9 in the diagnosis of pancreatic cancer. We conducted a comprehensive search to identify studies in which the pooled sensitivity, specificity, diagnostic odds ratio (DOR), and summary receiver operating curves (SROC) could be determined. A total of 11 studies that included 2,316 individuals who fulfilled all of the inclusion criteria were considered for analysis. The summary estimates for serum CA19-9 in the diagnosis of pancreatic cancer in these studies were pooled sensitivity 0.80 (95 % confidence interval [CI] 0.77–0.82), specificity 0.80 (95 % CI 0.77–0.82), and DOR 14.79 (95 % CI 8.55–25.59), and the area under the curve was 0.87. Our meta-analysis showed that serum CA19-9 plays important role in the diagnosis of pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28:645–56.

    Article  PubMed  Google Scholar 

  2. Bednar F, Simeone DM. Pancreatic cancer stem cell biology and its therapeutic implications. J Gastroenterol. 2011;46(12):1345–52.

    Article  PubMed  Google Scholar 

  3. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM, Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med. 2008;149:889–97.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Liao Q, Zhao YP, Yang YC, et al. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int. 2007;6:641–5.

    CAS  PubMed  Google Scholar 

  5. Wu X, Lu XH, Xu T, et al. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Chin J Dig Dis. 2006;7:170–4.

    Article  PubMed  Google Scholar 

  6. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31:164–9.

    Article  CAS  PubMed  Google Scholar 

  7. Jiang JT, Wu CP, Deng HF, et al. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J Gastroenterol. 2004;10:1675–7.

    CAS  PubMed  Google Scholar 

  8. Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int. 2004;3:464–8.

    CAS  PubMed  Google Scholar 

  9. Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology. 2003;50:1669–74.

    PubMed  Google Scholar 

  10. Banfi G, Bravi S, Ardemagni A, et al. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. Int J Biol Markers. 1996;11:77–81.

    CAS  PubMed  Google Scholar 

  11. Haglund C, Lundin J, Kuusela P, et al. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer. 1994;70:487–92.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Kawa S, Tokoo M, Hasebe O, et al. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer. 1994;70:481–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Banfi G, Zerbi A, Pastori S, et al. Behavior of tumor markers CA19.9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem. 1993;39:420–3.

    CAS  PubMed  Google Scholar 

  14. Rothlin MA, Joller H, Largiader F. CA 242 is a new tumor marker for pancreatic cancer. Cancer. 1993;71:701–7.

    Article  CAS  PubMed  Google Scholar 

  15. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg. 2003;138:951–5.

    Article  PubMed  Google Scholar 

  17. Micke O, Bruns F, Kurowski R, Horst E, deVries AF, Hausler JW, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003;57:90–7.

    Article  CAS  PubMed  Google Scholar 

  18. Magnani JL. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch Biochem Biophys. 2004;426:122–31.

    Article  CAS  PubMed  Google Scholar 

  19. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci. 2005;50:1734–40.

    Article  CAS  PubMed  Google Scholar 

  20. Nazli O, Bozdag AD, Tansug T, Kir R, Kaymak E. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology. 2000;47:1750–2.

    CAS  PubMed  Google Scholar 

  21. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol. 2005;15:300–8.

    Article  CAS  PubMed  Google Scholar 

  22. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci. 2004;49:1149–55.

    Article  CAS  PubMed  Google Scholar 

  23. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol. 2005;23:4524–31.

    Article  CAS  PubMed  Google Scholar 

  24. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, Fukushima N, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res. 2004;10:2386–92.

    Article  CAS  PubMed  Google Scholar 

  25. Koopmann J, White CN, Zhang Z, Canto MI, Brown DA, Hunter M, et al. Serum markers in patients with respectable pancreatic adenocarcinoma: MIC-1 vs. CA19-9. Clin Cancer Res. 2006;12:442–6.

    Article  CAS  PubMed  Google Scholar 

  26. Yamaguchi K, Enjoji M, Nakashima M, Nakamuta M, Watanabe T, Tanaka M. Novel serum tumor marker, RCAS1, in pancreatic diseases. World J Gastroenterol. 2005;11:5199–202.

    CAS  PubMed  Google Scholar 

  27. Kolb A, Kleeff J, Guweidhi A, Esposito I, Giese NA, Adwan H, et al. Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions. Cancer Biol Ther. 2005;4:740–6.

    Article  CAS  PubMed  Google Scholar 

  28. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13:487–91.

    CAS  PubMed  Google Scholar 

  29. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol. 2003;56(11):1129–35.

    Article  PubMed  Google Scholar 

  30. Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79:16–20.

    Article  PubMed  Google Scholar 

  31. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med. 2002;21:1237–56.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Liaoning Cancer Hospital and Institute, Shenyang, 110042, China

    Zhe Huang & Fang Liu

Authors
  1. Zhe Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhe Huang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Z., Liu, F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumor Biol. 35, 7459–7465 (2014). https://doi.org/10.1007/s13277-014-1995-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1995-9

Keywords

Search

Navigation